LCTX vs VRTX
LCTX: Lineage Cell Therapeutics is a clinical-stage biotech developing off-the-shelf, allogeneic cell therapies for degenerative diseases of the eye, spinal cord, and auditory system. VRTX: Vertex is a leader in biotechnology primarily recognized for its dominance in cystic fibrosis therapy and its emerging pipeline of gene-editing treatments and non-opioid pain relief.
Side-by-side fundamentals
| Metric | LCTX | VRTX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.03 | $503.25 | |
| Market cap | $260M | $127.6B | |
| P/E as of 2026-10-08 | n/a | 29.28 | |
| Net margin FY2025, SEC XBRL | -436.5% | +32.9% | VRTX higher |
| Gross margin FY2024, SEC XBRL | +96.5% | n/a | |
| Operating margin FY2025, SEC XBRL | -251.6% | +34.8% | VRTX higher |
| ROE FY2025, SEC XBRL | -146.6% | +21.2% | VRTX higher |
| ROA FY2025, SEC XBRL | -56.4% | +15.4% | VRTX higher |
| Debt / equity as of 2026-09-02 | 0.00 | 0.00 | VRTX lower |
| Revenue growth (YoY) as of 2026-09-02 | -37.1% | +10.2% | VRTX higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +10.4% | VRTX higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | 1.09 | 0.47 | |
| 1-year return as of 2026-10-08 close | -40.5% | +19.5% | VRTX higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.